Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04323657 · ClinicalTrials.gov registry record · Phase 1
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
A Phase 1 study of Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by TCR2 Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 3
- Study locations
NCT04323657 is a Phase 1 study of Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma that has completed, run by TCR2 Therapeutics. The registered enrollment target is 6 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04323657, a Phase 1 study of Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma, has completed, sponsored by TCR2 Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 3
- Study locations
Study Summary
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This is a Phase 1/2 open-label study to evaluate the safety of autologous genetically engineered TC-110 T cells in patients with aggressive NHL (DLBCL, PMBCL, TFL), high-risk indolent NHL (including MCL), or adult ALL.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG TC-110 T Cells
Study Locations (3)
Colorado
- Colorado Blood Cancer Institute - Denver
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-03-27 |
| Est. Completion | 2023-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04323657
The ClinicalTrials.gov registry entry for NCT04323657 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (98% lower). The listed sponsor is TCR2 Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04323657 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT04323657 about?
NCT04323657 is a clinical study titled "TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia". TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This is a Ph...
What is the current status of trial NCT04323657?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-03-27. Estimated completion is 2023-02-24.
What conditions does trial NCT04323657 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma.
What interventions are being tested in trial NCT04323657?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), TC-110 T Cells (DRUG).
Who is sponsoring clinical trial NCT04323657?
This trial is sponsored by TCR2 Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04323657 being conducted?
This trial has 3 study locations across Colorado, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
RECRUITING · Phase 1
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.